Single Use ERCP Performance -SURE Study
Launched by NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST · Dec 10, 2020
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
ERCP is a therapeutic endoscopic procedure done to establish either bile duct or pancreatic duct drainage or both. The indications for ERCP are bile duct stones, bile duct strictures, sphincter of Oddi manometry with sphincterotomy, bile leak, pancreatic duct stones and pancreatic duct stricture. The intended benefits of the procedure are either to relieve bile duct/ pancreatic duct obstruction or facilitate bile duct/ pancreatic duct drainage. It is a minimally invasive procedure and is associated with reduced morbidity compared to surgery.
Gall stones are made of cholesterol, pigment and...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Patients who are at high risk of post ERCP infection such as
- • Jaundice (Bilirubin \>21)
- • Primary sclerosing cholangitis
- • Post liver transplant anastomotic stricture
- • Inpatients
- • Combined procedures (Ex: ERCP+ spy glass cholangioscopy)
- • Previous inadequate biliary drainage.
- • Biliary stricture
- • Participant is willing and able to give informed consent for participation in the study.
- • Male or Female, aged 18 years or above.
- • Grade 1-3 ERCP on complexity grading (ASGE grading)
- • Able (in the Investigators opinion) and willing to comply with all study requirements.
- • Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.
- Exclusion Criteria:
- • Patients with CBD stones and no jaundice
- • Sphincter of Oddi manometry.
- • Female participants who is pregnant, lactating or planning pregnancy during the course of the study.
- • Patients who are unable to consent for the study.
- • ERCP for Pancreatic pathology.
- • Grade 4 complex ERCP (ASGE grading)
- • Participant who is terminally ill /ECOG 4
- • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
About Nottingham University Hospitals Nhs Trust
Nottingham University Hospitals NHS Trust is a leading healthcare provider in the UK, dedicated to delivering high-quality patient care and advancing medical research. Comprising two major hospitals, Queen's Medical Centre and Nottingham City Hospital, the Trust is at the forefront of clinical innovation and education. With a strong emphasis on translational research, Nottingham University Hospitals NHS Trust actively sponsors clinical trials aimed at improving treatment outcomes and understanding various health conditions. The Trust collaborates with academic institutions, healthcare professionals, and industry partners to foster a robust research environment that enhances clinical practice and contributes to evidence-based medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nottingham, , United Kingdom
Patients applied
Trial Officials
Suresh Vasan Venkatachalapathy, MRCP
Principal Investigator
Nottingham University Hospitals NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials